Outsourced Pharma Capacity Update Videos - Large Molecule

  1. Novartis Contract Manufacturing Capacity Update October 2025: Large Molecule 10/16/2025

    Gain insight into our global manufacturing network, including information about the capabilities of each mammalian and microbial site within the network.

  2. Northway Biotech Capacity Update October 2025: Large Molecule 10/16/2025

    André Markmann, VP of Business Development, shares insights drawn from over 20 years of experience, more than 185 successful projects, and fully integrated microbial and mammalian facilities in Waltham, Massachusetts, and Vilnius, Lithuania.

  3. MilliporeSigma Capacity Update October 2025: Large Molecule 10/16/2025

    Our global facilities are built to guide you when you’re ready to scale; and power your mRNA journey from discovery to global commercialization.

  4. KBI Biopharma Capacity Update October 2025: Large Molecule 10/16/2025

    Accelerate your biopharmaceutical program with a flexible, global manufacturing partner that minimizes risk, shortens timelines, and empowers seamless scaling from clinical to commercial production.

     

  5. Boehringer Ingelheim Biopharmaceuticals GmbH Capacity Update October 2025: Large Molecule 10/16/2025

    This session provides a comprehensive overview of our biopharmaceutical contract manufacturing services for mammalian cell culture and microbial technologies.

  6. Abzena Capacity Update October 2025: Large Molecule 10/16/2025

    Accelerate your therapeutic antibody and complex protein development with advanced mammalian cell line platforms that move from DNA to RCB in just 10 weeks.

  7. Novartis Contract Manufacturing Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Review biologics CDMO solutions and capacity offered by Novartis Contract Manufacturing. We discuss our capabilities in mammalian cell culture manufacturing and microbial fermentation.

  8. Providing Development And Supply Of Life-Changing Medicines 7/28/2025

    Review the strategic application of extensive expertise in microbial systems to meet the increasing demand for novel biologics. Cutting-edge capabilities ensure streamlined development and manufacturing processes.

  9. Cytovance Biologics Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Thomas Kohl, Director of Business Development, shares the company’s microbial and mammalian capabilities and their available capacity. Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.

  10. Aragen Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Aragen’s newly built cutting-edge biologics manufacturing facility launches with GMP capabilities from 50L to 2000L—scaling to 5000L soon—with a DP filling line and ADC conjugation suite set to redefine bioproduction in India.